perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”10.21508/1027-4065-2021-66-2-35-40perinatology-1371Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSВторичная гипероксалурия у детей: терапевтический потенциал пре- и пробиотиковThe secondary hyperoxaluria in children: the therapeutic potential of prebiotics and probioticshttps://orcid.org/0000-0002-8070-5785ОбуховаА. Н.ObukhovaA. N.

Обухова Анна Николаевна – асп. кафедры госпитальной педиатрии Приволжского исследовательского медицинского университета603950, БОКС-470, Нижний Новгород, пл. Минина и Пожарского, д. 10/1 

Nizhny Novgorod

obukhovaanna@mail.ruhttps://orcid.org/0000-0002-8531-3174ХалецкаяО. В.KhaletskayaO. V.

Халецкая Ольга Владимировна – д.м.н., проф., зав. кафедрой госпитальной педиатрии Приволжского исследовательского медицинского университета603950, БОКС-470, Нижний Новгород, пл. Минина и Пожарского, д. 10/1 

Nizhny Novgorod

ФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава РоссииРоссияPrivolzhsky Research Medical UniversityRussian Federation2021180520216623540Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20212021Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/1371

Цель работы состояла в представлении современных данных о способности про- и пребиотических препаратов предупреждать формирование вторичной гипероксалурии у детей. Для этого проведен анализ данных литературы с обобщением результатов оригинальных исследований, касающихся способности про- и пребиотиков предупреждать развитие и снижать выраженность лабораторных проявлений вторичной гипероксалурии путем улучшения состояния кишечной микрофлоры, участвующей в деградации оксалатов. Показана способность Oxalobacter formigenes, Lactobacillus spp. и Bifidobacterium spp. участвовать в метаболизме оксалатов, снижать экскрецию оксалатов с мочой, тем самым уменьшая выраженность лабораторных проявлений вторичной гипероксалурии. Представлена возможность терапевтической коррекции заболевания путем улучшения состояния кишечной микрофлоры как препаратами пробиотического действия, содержащими в своем составе штаммы Lactobacillus spp. и Bifidobacterium spp., так и пребиотическими средствами. Сделан вывод, что внедрение в терапию вторичной гипероксалурии препаратов, нормализующих состояние кишечной микрофлоры (про- и пребиотиков), поможет рационализировать тактику ведения пациентов и поспособствует уменьшению проявлений вторичной гипероксалурии.

The article presents modern data on the use of probiotic and prebiotic drugs to prevent the formation of secondary hyperoxaluria in children. The authors analyzed the literature data and generalized the available results of original studies on the use of probiotics and prebiotics to prevent the development and to reduce the laboratory manifestations of secondary hyperoxaluria by improving the state of the intestinal microflora involved in the degradation of oxalates. They demonstrated the ability of Oxalobacter formigenes, Lactobacillus spp. и Bifidobacterium spp. bacteria to participate in the metabolism of oxalates, to reduce the excretion of oxalates with the urine, thereby reducing the laboratory manifestations of secondary hyperoxaluria. The article shows the therapeutic correction of the disease by improving the state of the intestinal microflora with both probiotic preparations containing Lactobacillus spp. and Bifidobacterium spp. strains and prebiotic agents. The drugs that normalize the state of the intestinal microflora (probiotics and prebiotics) help to rationalize the management of patients with secondary hyperoxaluria and to reduce the manifestations of secondary hyperoxaluria.

детивторичная гипероксалуриямикрофлора кишечникапробиотикипребиотикиchildrensecondary hyperoxaluriaintestinal microfloraprobioticsprebioticsReferencesЮрьева Э.А., Длин В.В., Новикова Н.Н., Воздвиженская Е.С., Харабадзе М.Н., Князева Д.П. Обменные нефропатии у детей: причины развития, клинико-лабораторные проявления. Российский вестник перинатологии и педиатрии. 2016; 61(2): 28–34. [Yur’yeva E.A., Dlin V.V., Novikova N.N., Vozdvizhenskaya E.S., Kharabadze M.N., Knyazeva D.P. Metabolic nephropathies in children: causes of development, clinical and laboratory manifestations. Rossiyskiy vestnik perinatologii i pediatrii. 2016; 61(2): 28–34. (in Russ.)]Юрьева Э.А., Длин В.В., Новикова Н.Н., Воздвиженская Е.С., Харабадзе М.Н., Князева Д.П. Обменные нефропатии у детей: причины развития, клинико-лабораторные проявления. Российский вестник перинатологии и педиатрии. 2016; 61(2): 28–34. [Yur’yeva E.A., Dlin V.V., Novikova N.N., Vozdvizhenskaya E.S., Kharabadze M.N., Knyazeva D.P. Metabolic nephropathies in children: causes of development, clinical and laboratory manifestations. Rossiyskiy vestnik perinatologii i pediatrii. 2016; 61(2): 28–34. (in Russ.)]Длин В.В., Османов И.М. Дисметаболическая нефропатия с оксалатно-кальциевой кристаллурией. Эффективная фармакология 2013; 4(42): 8–16. [Dlin V.V., Osmanov I.M. Dysmetabolic nephropathy with oxalate-calcium crystalluria. Jeffektivnaya farmakologiya 2013; 4(42): 8–16. (in Russ.)]Длин В.В., Османов И.М. Дисметаболическая нефропатия с оксалатно-кальциевой кристаллурией. Эффективная фармакология 2013; 4(42): 8–16. [Dlin V.V., Osmanov I.M. Dysmetabolic nephropathy with oxalate-calcium crystalluria. Jeffektivnaya farmakologiya 2013; 4(42): 8–16. (in Russ.)]Степаненко В.М. Клинико-лабораторная характеристика обменной нефропатии у детей. Курортная медицина 2017; 3:150–157. [Stepanenko V.M. Clinical and laboratory characteristics of metabolic nephropathy in children. Kurortnaya meditsina 2017; 3:150–157. (in Russ.)]Степаненко В.М. Клинико-лабораторная характеристика обменной нефропатии у детей. Курортная медицина 2017; 3:150–157. [Stepanenko V.M. Clinical and laboratory characteristics of metabolic nephropathy in children. Kurortnaya meditsina 2017; 3:150–157. (in Russ.)]Аверьянова Н.И., Балуева Л.Г., Иванова Н.В., Рудавина Т.И. Нарушения обмена щавелевой кислоты у детей. Современные проблемы науки и образования 2015; 3: 174–179. [Aver’yanova N.I., Baluyeva L.G., Ivanova N.V.,Rudavina T.I. Disorders of oxalic acid metabolism in children. Sovremennye problemy nauki i obrazovaniya 2015; 3: 174–179. (in Russ.)]Аверьянова Н.И., Балуева Л.Г., Иванова Н.В., Рудавина Т.И. Нарушения обмена щавелевой кислоты у детей. Современные проблемы науки и образования 2015; 3: 174–179. [Aver’yanova N.I., Baluyeva L.G., Ivanova N.V.,Rudavina T.I. Disorders of oxalic acid metabolism in children. Sovremennye problemy nauki i obrazovaniya 2015; 3: 174–179. (in Russ.)]Юрьева Э.А., Морозов С.Л. Дисметаболические нефропатии у детей. Практика педиатра. 2017; 4: 34–38. [Yur’yeva E.A., Morozov S.L. Dysmetabolic nephropathies in children. Praktika pediatra. 2017; 4: 34–38. (in Russ.)]Юрьева Э.А., Морозов С.Л. Дисметаболические нефропатии у детей. Практика педиатра. 2017; 4: 34–38. [Yur’yeva E.A., Morozov S.L. Dysmetabolic nephropathies in children. Praktika pediatra. 2017; 4: 34–38. (in Russ.)]Длин В.В., Османов И.М., Чугунова О.Л. Инфекция мочевой системы у детей: Руководство для врачей. Под ред. В.В. Длина, И.М. Османова, О.Л. Чугуновой (сост. С.Л. Морозов). 2-е изд., доп. М.: Оверлей, 2017. [Dlin V.V., Osmanov I.M., Chugunova O.L. Urinary infection in children: a guide for physicians. Ed. V.V. Dlin, I.M. Osmanov, O.L. Chugunova (comp. S.L. Morozov). 2nd ed., suppl. M.: Overlei, 2017. (in Russ.)]Длин В.В., Османов И.М., Чугунова О.Л. Инфекция мочевой системы у детей: Руководство для врачей. Под ред. В.В. Длина, И.М. Османова, О.Л. Чугуновой (сост. С.Л. Морозов). 2-е изд., доп. М.: Оверлей, 2017. [Dlin V.V., Osmanov I.M., Chugunova O.L. Urinary infection in children: a guide for physicians. Ed. V.V. Dlin, I.M. Osmanov, O.L. Chugunova (comp. S.L. Morozov). 2nd ed., suppl. M.: Overlei, 2017. (in Russ.)]Suryavanshi M.V., Bhute S.S., Jadhav S.D., Bhatia M.S., Gune R.P., Shouche Y.S. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. Scientific Reports 2016; 6: 1–15Suryavanshi M.V., Bhute S.S., Jadhav S.D., Bhatia M.S., Gune R.P., Shouche Y.S. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. Scientific Reports 2016; 6: 1–15Mehta M., Nazzal L. The role of the microbiome in kidney stone formation. Int J Surg 2016; 36: 607–612 DOI: 10.1016/j.ijsu.2016.11.024Mehta M., Nazzal L. The role of the microbiome in kidney stone formation. Int J Surg 2016; 36: 607–612 DOI: 10.1016/j.ijsu.2016.11.024Miller A.W., Oakeson K.F., Dale C., Dearing M.D. Microbial community transplant results in increased and long-term oxalate degradation. Microb Ecol 2016; 72 (2): 470–478. DOI: 10.1007/s00248-016-0800-2Miller A.W., Oakeson K.F., Dale C., Dearing M.D. Microbial community transplant results in increased and long-term oxalate degradation. Microb Ecol 2016; 72 (2): 470–478. DOI: 10.1007/s00248-016-0800-2Zhao C., Yang H., Zhu X., Li Y., Wang N., Han S. et al. Oxalate-degrading enzyme recombined lactic acid bacteria strains reduce hyperoxaluria. Urology 2018; 113: 253.e1–253.e7. DOI: 10.1016/j.urology.2017.11.038Zhao C., Yang H., Zhu X., Li Y., Wang N., Han S. et al. Oxalate-degrading enzyme recombined lactic acid bacteria strains reduce hyperoxaluria. Urology 2018; 113: 253.e1–253.e7. DOI: 10.1016/j.urology.2017.11.038Cresci G., Bawden Е. Gut microbiome: what we do and don’t know. Nutr Clin Pract 2015; 30 (6): 734–746. DOI: 10.1177/0884533615609899Cresci G., Bawden Е. Gut microbiome: what we do and don’t know. Nutr Clin Pract 2015; 30 (6): 734–746. DOI: 10.1177/0884533615609899Milani C., Duranti S., Bottacini F., Casey E., Turroni F., Mahony J. et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev 2017; 81(4): 1–67. DOI: 10.1128/MMBR.00036-17Milani C., Duranti S., Bottacini F., Casey E., Turroni F., Mahony J. et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev 2017; 81(4): 1–67. DOI: 10.1128/MMBR.00036-17Assimos D.G. Oxalobacter formigenes-Associated Host Features and Microbial Community Structures Examined Using the American Gut Project. J Urol 2018; 199(4):888. DOI: 10.1016/j.juro.2018.01.037Assimos D.G. Oxalobacter formigenes-Associated Host Features and Microbial Community Structures Examined Using the American Gut Project. J Urol 2018; 199(4):888. DOI: 10.1016/j.juro.2018.01.037Liu M., Koh H., Kurtz Z.D., Battaqlia T., PeBenito A., Li H. et al. Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project. Microbiome 2017; 5(1):108. DOI: 10.1186/s40168-017-0316-0Liu M., Koh H., Kurtz Z.D., Battaqlia T., PeBenito A., Li H. et al. Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project. Microbiome 2017; 5(1):108. DOI: 10.1186/s40168-017-0316-0Sadaf H., Raza S., Hassan S. Role of gut microbiota against calcium oxalate. Microb Pathog 2017; 109: 287–291. DOI: 10.1016/j.micpath.2017.06.009Sadaf H., Raza S., Hassan S. Role of gut microbiota against calcium oxalate. Microb Pathog 2017; 109: 287–291. DOI: 10.1016/j.micpath.2017.06.009Klimesova K., Whittamore J., Hatch M. Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria. Urolithiasis 2015; 43(2): 107–117. DOI: 10.1007/s00240-014-0728-2Klimesova K., Whittamore J., Hatch M. Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria. Urolithiasis 2015; 43(2): 107–117. DOI: 10.1007/s00240-014-0728-2Sasikumar P., Gomathi S., Anbazhagan K., Abhishek A., Paul E., Vasudevan V. et al. Recombinant Lactobacillus plantarum expressing and secreting heterologous oxalate de- carboxylase prevents renal calcium oxalate stone deposition in experimental rats. J Biomed Sci 2014; 30: 86–99. DOI: 10.1186/s12929-014-0086-ySasikumar P., Gomathi S., Anbazhagan K., Abhishek A., Paul E., Vasudevan V. et al. Recombinant Lactobacillus plantarum expressing and secreting heterologous oxalate de- carboxylase prevents renal calcium oxalate stone deposition in experimental rats. J Biomed Sci 2014; 30: 86–99. DOI: 10.1186/s12929-014-0086-yРымашевский А.Н., Набока Ю.Л., Продеус А.П., Свирава Э.Г. Бактериальное приданое новорожденного. Смена парадигмы: нестерильность плода как норма. Status Praesens. Педиатрия и неонатология 2017; 2(41): 23–29. [Ry- mashevskiy A.N., Naboka Yu.L., Prodeus A.P., Svirava E.G. Bacterial dowry of the newborn. Paradigm shift: non-sterility of the fetus as the norm. Status Praesens. Pediatriya i neonatologiya 2017; 2(41): 23–29. (in Russ.)]Рымашевский А.Н., Набока Ю.Л., Продеус А.П., Свирава Э.Г. Бактериальное приданое новорожденного. Смена парадигмы: нестерильность плода как норма. Status Praesens. Педиатрия и неонатология 2017; 2(41): 23–29. [Ry- mashevskiy A.N., Naboka Yu.L., Prodeus A.P., Svirava E.G. Bacterial dowry of the newborn. Paradigm shift: non-sterility of the fetus as the norm. Status Praesens. Pediatriya i neonatologiya 2017; 2(41): 23–29. (in Russ.)]Беляева И.А., Бомбардирова Е.П., Турти Т.В., Потехина Т.В. Кишечная микробиота у недоношенных детей – современное состояние проблемы. Педиатрическая фармакология 2015; 3(12): 296–303. [Belyayeva I.A., Bombardirova E.P., Turti T.V., Potekhina T.V. Intestinal microbiota in premature babies-the current state of the problem. Pediatricheskaya farmakologiya 2015; 3(12): 296–303. (in Russ.)]Беляева И.А., Бомбардирова Е.П., Турти Т.В., Потехина Т.В. Кишечная микробиота у недоношенных детей – современное состояние проблемы. Педиатрическая фармакология 2015; 3(12): 296–303. [Belyayeva I.A., Bombardirova E.P., Turti T.V., Potekhina T.V. Intestinal microbiota in premature babies-the current state of the problem. Pediatricheskaya farmakologiya 2015; 3(12): 296–303. (in Russ.)]Moossavi S., Azad M.B. Origins of human milk microbiota: new evidence and arising questions. Gut Microbes 2019; 4: 1–10. DOI: 10.1080/19490976.2019.1667722Moossavi S., Azad M.B. Origins of human milk microbiota: new evidence and arising questions. Gut Microbes 2019; 4: 1–10. DOI: 10.1080/19490976.2019.1667722Turroni F., Milani C., Ferrario S., Lugli G.A., Mancabelli L., van Sinderen D. et al. Bifidobacteria and the infant gut: an example of co-evolution and natural selection. Cell Mol Life Sci 2018; 75(1): 103–118. DOI: 10.1007/s00018-017-2672-0Turroni F., Milani C., Ferrario S., Lugli G.A., Mancabelli L., van Sinderen D. et al. Bifidobacteria and the infant gut: an example of co-evolution and natural selection. Cell Mol Life Sci 2018; 75(1): 103–118. DOI: 10.1007/s00018-017-2672-0Макарова С.Г., Намазова-Баранова Л.С. Кишечная микробиота и использование пробиотиков в практике педиатра. Что нового? Педиатрическая фармакология 2015; 1(12): 38–45. [Makarova S.G., Namazova-Baranova L.S. Intestinal microbiota and the use of probiotics in pediatrician practice. What’s new? Pediatricheskaya farmakologiya 2015; 1(12): 38–45. (in Russ.)]Макарова С.Г., Намазова-Баранова Л.С. Кишечная микробиота и использование пробиотиков в практике педиатра. Что нового? Педиатрическая фармакология 2015; 1(12): 38–45. [Makarova S.G., Namazova-Baranova L.S. Intestinal microbiota and the use of probiotics in pediatrician practice. What’s new? Pediatricheskaya farmakologiya 2015; 1(12): 38–45. (in Russ.)]Donovan S.M. Introduction to the special focus issue on the impact of diet on gut microbiota composition and function and future opportunities for nutritional modulation of the gut microbiome to improve human health. Gut Microbes 2017; 8(2): 75–81. DOI: 10.1080/19490976.2017.1299309Donovan S.M. Introduction to the special focus issue on the impact of diet on gut microbiota composition and function and future opportunities for nutritional modulation of the gut microbiome to improve human health. Gut Microbes 2017; 8(2): 75–81. DOI: 10.1080/19490976.2017.1299309Singh R.K., Chang H.W., Yan D., Lee K.M., Ucmak D., Wong K. et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med 2017; 15(1): 73– 90. DOI: 10.1186/s12967-017-1175-ySingh R.K., Chang H.W., Yan D., Lee K.M., Ucmak D., Wong K. et al. Influence of diet on the gut microbiome and implications for human health. J Transl Med 2017; 15(1): 73– 90. DOI: 10.1186/s12967-017-1175-yLieske J.C. Probiotics for prevention of urinary stones. Transl Med 2017; 5(2): 1–8. DOI: 10.21037/atm.2016.11.86Lieske J.C. Probiotics for prevention of urinary stones. Transl Med 2017; 5(2): 1–8. DOI: 10.21037/atm.2016.11.86Rodríguez J.M. Probiotics: from the lab to the consumer. Nutr Hosp 2015; 31: 33–47. DOI: 10.3305/nh.2015.31.sup1.8705Rodríguez J.M. Probiotics: from the lab to the consumer. Nutr Hosp 2015; 31: 33–47. DOI: 10.3305/nh.2015.31.sup1.8705Shokryazdan P., Faseleh Jahromi M., Liang J.B., Ho Y.W. Probiotics: From Isolation to Application. J Am Coll Nutr 2017; 36(8): 666–676. DOI: 10.1080/07315724.2017.1337529Shokryazdan P., Faseleh Jahromi M., Liang J.B., Ho Y.W. Probiotics: From Isolation to Application. J Am Coll Nutr 2017; 36(8): 666–676. DOI: 10.1080/07315724.2017.1337529Brunser O. Probiotics: innocuousness, prevention and risks. Rev Chil Pediatr 2017; 88(4): 534–540. DOI: 10.4067/S0370-41062017000400015Brunser O. Probiotics: innocuousness, prevention and risks. Rev Chil Pediatr 2017; 88(4): 534–540. DOI: 10.4067/S0370-41062017000400015Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J. et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017; 14(8): 491–502. DOI: 10.1038/nrgastro.2017.75Gibson G.R., Hutkins R., Sanders M.E., Prescott S.L., Reimer R.A., Salminen S.J. et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017; 14(8): 491–502. DOI: 10.1038/nrgastro.2017.75Markowiak P., Śliżewska К. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients 2017; 9(9): 1021– 1051. DOI: 10.3390/nu9091021Markowiak P., Śliżewska К. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients 2017; 9(9): 1021– 1051. DOI: 10.3390/nu9091021Matsuda K. PCR-Based detection methods for single-nucleotide polymorphism or mutation: real-time PCR and its substantial contribution toward technological refinement. Adv Clin Chem 2017; 80: 45–72. DOI: 10.1016/bs.acc.2016.11.002Matsuda K. PCR-Based detection methods for single-nucleotide polymorphism or mutation: real-time PCR and its substantial contribution toward technological refinement. Adv Clin Chem 2017; 80: 45–72. DOI: 10.1016/bs.acc.2016.11.002Krawczyk B., Kur J., Stojowska-Swedrzynska K., Spibida M. Principles and applications of ligation mediated PCR methods for DNA-based typing of microbial organisms. Acta Biochim Pol 2016; 17; 63(1): 39–52. DOI: 10.18388/abp.2015_1192Krawczyk B., Kur J., Stojowska-Swedrzynska K., Spibida M. Principles and applications of ligation mediated PCR methods for DNA-based typing of microbial organisms. Acta Biochim Pol 2016; 17; 63(1): 39–52. DOI: 10.18388/abp.2015_1192Garofalo C., Bancalari E., Milanovic V., Cardinali F., Osimani A., Savo Sardaro M. L. et al. Study of the bacterial diversity of foods: PCR-DGGE versus LH-PCR. Int J Food Microbiol 2017; 2: 24–36. DOI: 10.1016/j.ijfoodmicro.2016.11.008Garofalo C., Bancalari E., Milanovic V., Cardinali F., Osimani A., Savo Sardaro M. L. et al. Study of the bacterial diversity of foods: PCR-DGGE versus LH-PCR. Int J Food Microbiol 2017; 2: 24–36. DOI: 10.1016/j.ijfoodmicro.2016.11.008Padilha M., Villarreal Morales M.L., Silva Vieira A.D., Maia Costa M.G., Isay Saad S.M. A prebiotic mixture improved Lactobacillus acidophilus and Bifidobacterium animalis gastrointestinal in vitro resistance in petit-suisse. Food Funct 2016; 7(5): 2312–2319. DOI: 10.1039/c5fo01592hPadilha M., Villarreal Morales M.L., Silva Vieira A.D., Maia Costa M.G., Isay Saad S.M. A prebiotic mixture improved Lactobacillus acidophilus and Bifidobacterium animalis gastrointestinal in vitro resistance in petit-suisse. Food Funct 2016; 7(5): 2312–2319. DOI: 10.1039/c5fo01592hCherdyntseva T.A., Kotova I.B., Netrusov A.I. The isolation, identification and analyses of Lactobacillus genus bacteria with probiotic potential. Adv Exp Med Biol 2016; 897: 103– 111. DOI: 10.1007/5584_2015_5008Cherdyntseva T.A., Kotova I.B., Netrusov A.I. The isolation, identification and analyses of Lactobacillus genus bacteria with probiotic potential. Adv Exp Med Biol 2016; 897: 103– 111. DOI: 10.1007/5584_2015_5008Гасилина Т.В., Бельмер С.В. Коррекции нарушений кишечного микробиоценоза: значение метаболических пробиотиков. Практика педиатра 2016; 4: 53–58. [Gasilina T.V., Bel’mer S.V. Correction of intestinal microbiocenosis disorders: the value of metabolic probiotics. Praktika pediatra 2016; 4: 53–58. (in Russ.)]Гасилина Т.В., Бельмер С.В. Коррекции нарушений кишечного микробиоценоза: значение метаболических пробиотиков. Практика педиатра 2016; 4: 53–58. [Gasilina T.V., Bel’mer S.V. Correction of intestinal microbiocenosis disorders: the value of metabolic probiotics. Praktika pediatra 2016; 4: 53–58. (in Russ.)]Di Cerbo A., Palmieri B., Aponte M., Morales-Medina J.C., Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol 2016; 69(3): 187–203. DOI: 10.1136/jclinpath-2015-202976Di Cerbo A., Palmieri B., Aponte M., Morales-Medina J.C., Iannitti T. Mechanisms and therapeutic effectiveness of lactobacilli. J Clin Pathol 2016; 69(3): 187–203. DOI: 10.1136/jclinpath-2015-202976Klimesova K., Whittamore J.M., Hatch M. Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria. Urolithiasis 2015; 43(2): 107–117. DOI: 10.1007/s00240-014-0728-2Klimesova K., Whittamore J.M., Hatch M. Bifidobacterium animalis subsp. lactis decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria. Urolithiasis 2015; 43(2): 107–117. DOI: 10.1007/s00240-014-0728-2Sanders M.E. Probiotics and microbiota composition. BMC Med 2016; 14(1): 82–84. DOI: 10.1186/s12916-016-0629-zSanders M.E. Probiotics and microbiota composition. BMC Med 2016; 14(1): 82–84. DOI: 10.1186/s12916-016-0629-zBindels L.B., Delzenne N.M., Cani P.D., Walter J. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol 2015; 12: 303–310. DOI: 10.1038/nrgastro.2015.47Bindels L.B., Delzenne N.M., Cani P.D., Walter J. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol 2015; 12: 303–310. DOI: 10.1038/nrgastro.2015.47Orel R., Reberšak L. Clinical effects of prebiotics in pediatric population. Indian Pediatr 2016; 53(12): 1083–1089Orel R., Reberšak L. Clinical effects of prebiotics in pediatric population. Indian Pediatr 2016; 53(12): 1083–1089Rasmussen H.E., Hamaker B.R. Prebiotics and inflammatory bowel disease. Gastroenterol Clin North Am 2017; 46(4): 783–795. DOI: 10.1016/j.gtc.2017.08.004Rasmussen H.E., Hamaker B.R. Prebiotics and inflammatory bowel disease. Gastroenterol Clin North Am 2017; 46(4): 783–795. DOI: 10.1016/j.gtc.2017.08.004Holscher H.D. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes 2017; 8(2): 172–184. DOI: 10.1080/19490976.2017.1290756Holscher H.D. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes 2017; 8(2): 172–184. DOI: 10.1080/19490976.2017.1290756Singla V., Chakkaravarthi S. Applications of prebiotics in food industry: a review. Food Sci Technol Int 2017; 23(8): 649– 667. DOI: 10.1177/1082013217721769Singla V., Chakkaravarthi S. Applications of prebiotics in food industry: a review. Food Sci Technol Int 2017; 23(8): 649– 667. DOI: 10.1177/1082013217721769Wegh C.A.M., Schoterman M.H.C., Vaughan E.E., Belzer C., Benninga M.A. The effect of fiber and prebiotics on children’s gastrointestinal disorders and microbiome. Expert Rev Gastroenterol Hepatol 2017; 11(11): 1031–1045. DOI: 10.1080/17474124.2017.1359539Wegh C.A.M., Schoterman M.H.C., Vaughan E.E., Belzer C., Benninga M.A. The effect of fiber and prebiotics on children’s gastrointestinal disorders and microbiome. Expert Rev Gastroenterol Hepatol 2017; 11(11): 1031–1045. DOI: 10.1080/17474124.2017.1359539Herve V., Junier T., Bindschedler S., Verrecchia E., Junier P. Diversity and ecology of oxalotrophic bacteria. World J Microbiol Biotechnol 2016; 32(2): 28–36. DOI: 10.1007/s11274-015-1982-3Herve V., Junier T., Bindschedler S., Verrecchia E., Junier P. Diversity and ecology of oxalotrophic bacteria. World J Microbiol Biotechnol 2016; 32(2): 28–36. DOI: 10.1007/s11274-015-1982-3Arvans D., Jung Y.C., Antonopoulos D., Koval J., Granja I., Bashir M. et al. Oxalobacter formigenes – derived bioactive factors stimulate oxalate transport by intestinal epithelial cells. J Am Soc Nephrol 2017; 28(3): 876–887. DOI: 10.1681/ASN.2016020132Arvans D., Jung Y.C., Antonopoulos D., Koval J., Granja I., Bashir M. et al. Oxalobacter formigenes – derived bioactive factors stimulate oxalate transport by intestinal epithelial cells. J Am Soc Nephrol 2017; 28(3): 876–887. DOI: 10.1681/ASN.2016020132Turroni F., Milani C., Duranti S., Mancabelli L., Mangifesta M., Viapppiani A. et al. Deciphering bifidobacterial-mediated metabolic interactions and their impact on gut microbiota by a multi-omics approach. ISME J 2016; 10(7): 1656–1668. DOI: 10.1038/ismej.2015.236Turroni F., Milani C., Duranti S., Mancabelli L., Mangifesta M., Viapppiani A. et al. Deciphering bifidobacterial-mediated metabolic interactions and their impact on gut microbiota by a multi-omics approach. ISME J 2016; 10(7): 1656–1668. DOI: 10.1038/ismej.2015.236Jairath A., Parekh N., Otano N., Mishra S., Ganpule A., Sabnis R. et al. Oxalobacter formigenes: opening the door to probiotic therapy for the treatment of hyperoxaluria. J Urol 2015; 49(4): 334–337. DOI: 10.3109/21681805.2014.996251Jairath A., Parekh N., Otano N., Mishra S., Ganpule A., Sabnis R. et al. Oxalobacter formigenes: opening the door to probiotic therapy for the treatment of hyperoxaluria. J Urol 2015; 49(4): 334–337. DOI: 10.3109/21681805.2014.996251Assimos D.G. Oxalobacter formigenes: opening the door to probiotic therapy for the treatment of hyperoxaluria. J Urol 2015; 194(2): 424–425. DOI: 10.1016/j.juro.2015.05.039Assimos D.G. Oxalobacter formigenes: opening the door to probiotic therapy for the treatment of hyperoxaluria. J Urol 2015; 194(2): 424–425. DOI: 10.1016/j.juro.2015.05.039

The authors declare that there are no conflicts of interest present.